Delay in decision on ferric carboxymaltose (Ferinject) funding proposal
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to list ferric carboxymaltose (Ferinject) 500 mg per 10 ml vial in Section H of the Pharmaceutical Schedule from 1 July 2014 for the treatment of iron deficiency anaemia.
Consultation on this proposal has now closed. We received a large number of detailed responses during consultation, and we require additional time to fully consider these responses before a decision can be made on the proposal.
This delay will mean that a decision will not be made in time for 1 July 2014 funding changes. We expect a decision to be made, and subsequently notified, on this proposal within the next month.
If you have any questions about this notification, please contact Caroline De Luca, Therapeutic Group Manager, by email at email@example.com.